These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19506476)

  • 1. Prevention and treatment of invasive fungal diseases in neutropenic patients.
    Almyroudis NG; Segal BH
    Curr Opin Infect Dis; 2009 Aug; 22(4):385-93. PubMed ID: 19506476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
    Karthaus M; Hentrich M
    Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
    Rieger CT; Ostermann H
    Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
    Almyroudis NG; Segal BH
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical antifungal therapy in febrile neutropenic patients: current status.
    Kibbler CC
    Curr Top Med Mycol; 1997 Dec; 8(1-2):5-14. PubMed ID: 9504062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing.
    Cordonnier C; Robin C; Alanio A; Bretagne S
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():27-35. PubMed ID: 24283975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of mycoses in surgical patients -- review of the literature.
    Holzheimer RG; Dralle H
    Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ; MacDougall C; Gallagher JC
    Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Azole antifungal agents in the prevention of fungal infections in neutropenic patients and bone marrow graft recipients].
    Lortholary O; Dupont B
    Ann Med Interne (Paris); 1997; 148(3):258-67. PubMed ID: 9255336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis and treatment of invasive fungal infection in neutropenic patients].
    Vallejo C; Rovira M
    Rev Esp Quimioter; 2010 Dec; 23(4):177-83. PubMed ID: 21191555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Sugar AM
    Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practice in treating infants and children with proven, probable or suspected invasive fungal infections.
    Katragkou A; Roilides E
    Curr Opin Infect Dis; 2011 Jun; 24(3):225-9. PubMed ID: 21455060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Murali S; Langston A
    Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive fungal infection--laboratory diagnosis and antifungal treatment.
    Shao PL; Huang LM; Hsueh PR
    J Microbiol Immunol Infect; 2006 Jun; 39(3):178-88. PubMed ID: 16783447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.